Connecticut chronic-opioid treatment agreements and care plans, documented from statute outward
Status: Connecticut evidence build reviewed through October 4, 2026. This library separates the statutory 12-week agreement/care-plan requirement, prescription-monitoring duties, initial opioid-prescribing limits, professional guidance, legislative history, and the formal change path.
Current legal baseline
CGS §20-14s requires a prescribing practitioner who treats pain with an opioid drug for more than 12 weeks to establish a treatment agreement with the patient or discuss a care plan for chronic opioid use. The agreement or care plan must be documented in the medical record.
| Required subject | Current Connecticut statute |
|---|---|
| Treatment goals | Required. |
| Risks of opioid use | Required. |
| Urine drug screens | Must be addressed in the agreement or care plan. |
| Expectations for continued opioid treatment | Required. |
| Discontinuation circumstances | Must be addressed. |
| Nonopioid options | Must be addressed to the extent possible. |
| Medical-record documentation | Required. |
Connecticut state-level records
- Connecticut Treatment Agreement or Care Plan Requirement
- Connecticut Twelve-Week Trigger and Required Contents Record
- Connecticut PDMP and Continuous-Treatment Monitoring Record
- Connecticut Prescriber Scope and Opioid-Prescribing Limits Record
- Connecticut Drug Control Prescribing Guide Implementation Record
- Connecticut Medical Examining Board Pain-Management Guidance Record
- Connecticut Legislative History and Nonopioid Expansion Record
- Connecticut Contract-for-Care Authority and Change-Path Record
The central Connecticut distinction
Connecticut does not mandate one specific signed “pain contract” form. The statute permits either a treatment agreement or a documented chronic-opioid care-plan discussion. The same minimum subjects must still be covered and documented.
No universal one-pharmacy or fixed-testing rule in §20-14s
The statute does not itself require a one-pharmacy policy, patient signature, pill counts, a fixed urine-testing frequency, lost-medication restrictions, cannabis prohibitions, or automatic discharge. Those conditions may appear in professional guidance or individual practice policy and must be classified separately.
PDMP is a separate legal layer
Connecticut requires CPMRS review before many controlled-substance prescriptions exceeding 72 hours and at least once every 90 days during continuous or prolonged controlled-substance treatment. Those monitoring duties begin independently of the 12-week treatment-agreement threshold.
Initial opioid prescribing rules
Connecticut separately limits a first outpatient opioid prescription to seven days for adults and five days for minors, subject to documented clinical exceptions including chronic pain, cancer-related pain, and palliative care. Practitioners must also discuss addiction and overdose risks and encourage patients to obtain an opioid antagonist.
Current implementation evidence
The Department of Consumer Protection Drug Control Division’s current prescribing guide repeats the 12-week agreement-or-care-plan rule and describes urine screening as a subject to address rather than a single universal fixed testing schedule.
Professional-guidance background
The Connecticut Medical Examining Board continues to post older pain-management guidance encouraging individualized care, periodic review, and—in higher-risk patients—consideration of written agreements, one prescriber/one pharmacy when possible, monitoring, refill rules, and discontinuation criteria. Because that statement predates the 2019 statute, it is preserved as professional background rather than treated as the source of the modern legal mandate.
Legislative history
Public Act 19-191 created §20-14s effective October 1, 2019. Public Act 22-108 later added chiropractic and spinal cord stimulation to the nonopioid treatment options named in the statute. Public Act 23-195 made a technical change without altering the core requirement.
Current authority and change path
Because the mandate is statutory, repeal or narrowing requires action by the Connecticut General Assembly. The current Public Health Committee co-chairs are Sen. Saud Anwar and Rep. Cristin McCarthy Vahey. DPH Commissioner Manisha Juthani, MD; DCP Commissioner Bryan T. Cafferelli; and Connecticut Medical Examining Board Chair Kathryn Emmett, Esq. hold important implementation or enforcement roles but cannot repeal §20-14s administratively.
Practice-agreement evidence gap
The current official Connecticut record is strong, but reliable currently distributed clinic-specific agreement forms are less readily available publicly. This library does not fill that gap with generic national forms or stale documents. Current Connecticut practice agreements and care-plan forms will be added when their provenance and present use can be verified.
Submit a missing Connecticut agreement or care plan
Submit a Connecticut Contract for Care
Primary Connecticut authorities
- CGS §20-14s and related opioid-prescribing statutes
- Connecticut DCP — Laws Impacting Prescribing and Practice
- Connecticut Drug Control Division — Prescribing Controlled Substances
- Connecticut OLR — Connecticut’s Opioid Drug Abuse Laws (2026)
Reviewed: October 4, 2026.
Evidence boundary: Connecticut’s statutory requirement is an agreement-or-care-plan requirement after more than 12 weeks of opioid treatment for pain. PDMP duties, initial-supply limits, professional guidance, and clinic-added terms remain distinct evidence layers.